The compulsive nature of tobacco use is attributable to nicotine addiction. Nicotine is eliminated by metabolism through the cytochrome P450 2A6 (CYP2A6) enzyme in liver. Inhibition of CYP2A6 by chemical compounds may represent a potential supplement to anti-smoking therapy. The purpose of this study was to rationally design potent inhibitors of CYP2A6. 3D-QSAR models were constructed to find out which structural characteristics are important for inhibition potency. Specifically located hydrophobic and hydrogen donor features were found to affect inhibition potency. These features were used in virtual screening of over 60 000 compounds in the Maybridge chemical database. A total of 22 candidate molecules were selected and tested for inhibition potency. Four of these were potent and selective CYP2A6 inhibitors with IC 50 values lower than 1 mM. They represent novel structures of CYP2A6 inhibitors, especially N1-(4-fluorophenyl)cyclopropane-1-carboxamide. This compound can be used as a lead in the design of CYP2A6 inhibitor drugs to combat nicotine addiction.
Introduction
According to the World Health Organization (WHO), one-third of the global population over 15 years of age are smokers. 1 Nicotine is the primary compound present in tobacco, and it plays a crucial role in establishing and maintaining tobacco dependence. Various nicotine preparations have been developed as medications to assist in smoking cessation. Nicotine has also been evaluated in the treatment of a variety of medical disorders. 2 Understanding the pattern of nicotine metabolism and the sources of variations of this metabolism is important because of the key role of nicotine in producing tobacco dependence. Nicotine is eliminated by metabolism, and in humans, the key metabolite of nicotine is cotinine. The transformation of nicotine to cotinine involves two steps. The first step is its 5 0 -oxidation to produce 5 0 -hydroxynicotine and the nicotine-D 1 0 (5 0 ) -iminium ion. This reaction is mediated by the cytochrome P450 2A6 (CYP2A6) enzyme. [3] [4] [5] The second step, formation of cotinine, is catalysed by cytosolic aldehyde oxidase. 6 Several variant alleles of the CYP2A6 gene have been characterised, causing reduced or absent enzyme activity. [7] [8] [9] [10] Individuals with genetically inactivated CYP2A6 are slower at converting nicotine to cotinine. 11 It has been shown that nicotine-dependent slow inactivators, that is individuals with at least one inactive CYP2A6 allele, smoke fewer cigarettes. 12 Slow nicotine inactivators also smoke for a shorter duration before giving up smoking, are found more often among former smokers, and have increased success in quitting smoking during clinical trials. [13] [14] [15] There is growing evidence that the protection offered by slow metabolism can be mimicked by inhibiting CYP2A6 activity in vivo with chemical inhibitors. 16 Proof-ofconcept studies have been carried out with the CYP2A6 inhibitors methoxsalen (used in the treatment of psoriasis) and tranylcypromine (a monoamine oxidase inhibitor used in the treatment of depression). 12, 16, 17 Based on this data, a drug that acts as an inhibitor of CYP2A6 could be used for two purposes: (1) to make it possible to administer of nicotine in a tablet form by mouth by increasing its oral bioavailability, and (2) as a drug to be taken during smoking, reducing the amount of cigarettes smoked and thus diminishing the adverse health effects of smoking. In both cases, with or without nicotine augmentation, CYP2A6 inhibitors should decrease levels of smoking, promote cessation and reduce procarcinogen activation. 11, 16, 17 Several compounds have been tested for their inhibitory effects on the CYP2A6 enzyme in vitro. [18] [19] [20] We have previously carried out quantitative structure-activity relationship (QSAR) analysis of inhibitors of the human CYP2A6 and mouse CYP2A5 enzymes. [21] [22] [23] The purpose of this study was to rationally design novel potent inhibitors of CYP2A6. Protein homology modelling and three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis were carried out to determine which structural features are important for the inhibition potency. Data from these models were used to carry out structure-based screening from a chemical database to search for novel types of inhibitors. Four novel potent and selective inhibitors were identified. These compounds can serve as lead structures in developing clinically useful CYP2A6 inhibitors.
Results
Comparison between homology model and crystal structure After we had constructed the CYP2A6 homology model combined with the initial 3D-QSAR model and structurebased screening, the 3D structure of CYP2A6 co-crystallised with coumarin and with methoxsalen was published. 24 Later three other CYP2A6 structures co-crystallised with N,N-dimethyl(5-(pyridin-3-yl)furan-2-yl)methamine, N-dimethyl(5-(pyridin-3-yl)furan-2-yl)methamine, dimethyl(5-(pyridin-3-yl)furan-2-yl)methamine were published. 25 In our homology model, the side chain of Thr106 forms a hydrogen bond with the ligand. The crystal structure revealed the hydrogen bonds between the ligand and the side chain of Asn297. To obtain more accurate data on ligand orientation and hydrogen bonding, we created also a new 3D-QSAR model by docking molecules into the crystal structure.
Statistics of CoMFA and CoMSIA models
To determine which structural features are important for inhibition potency, two 3D-QSAR models (Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA)) were developed based on the CYP2A6 homology model. The stability of the models was tested by cross-validation with two and five groups ( Table 1) . As described previously, 26 the crossvalidation procedure provides a reliable picture of the predictivity of QSAR models. All the statistical values obtained from our current CoMFA and CoMSIA models Table 1 ). The leave-some-out (LSO) and leave-one-out (LOO) methods gave statistically the most significant CoMFA models. Since the LSO method was more stringent than the LOO method, the LSO model with four components was chosen for the final model. Also the leavehalf-out (LHO) method has been reported to give a good estimation of the model predictivity. 27, 28 The CoMSIA model yielded slightly lower statistical values than the CoMFA model.
CoMFA and CoMSIA fields 3D colour contour maps of the CoMFA and CoMSIA models with nicotine as the reference structure are illustrated in Figures 1 and 2 . Figure 1 shows the steric and electrostatic contour maps. Green and yellow areas denote steric interactions. Bulkier groups in the green area in the vicinity of the five-member ring enhance the potency of inhibitor. The steric fields suggest that inhibition potency increases if the green area of the steric fields is occupied by a hydrophobic group.
Red regions in Figure 1 indicate areas where an increase in electronegativity enhances inhibition potency and blue regions where electronegativity decreases inhibition potency. There are two large red areas where negative charge is favourable for inhibition. The first area is located at the site of metabolism in the five-member ring of nicotine, and the second one is close to the nitrogen atom of the pyridine ring. Both red and blue areas were associated with the presence of hydrogen bonds between inhibitor and protein.
More detailed information about the position of the hydrogen bond acceptors is provided in the CoMSIA model ( Figure 2 ). An acceptor group in the inhibitor, illustrated as a magenta region in the contour maps, increases inhibition potency. Red colour denotes the area where hydrogen acceptors decrease inhibition potency.
When assessing the CoMFA and CoMSIA fields together, it is evident that hydrogen bonding near the nitrogen atom of the pyrimidine ring in nicotine together with bulkiness near the five-member ring is crucial for potent inhibitors. A 3D database query was created to search for novel CYP2A6 inhibitor structures using these features. Specific hydrophobicity, acceptor/donor and planar characteristics that influence inhibitor potency were set in this query ( Figure 3 ). The query features contained a plane and hydrophobic sites which are illustrated as the larger grey sphere in Figure 3 . The hydrophobic features in the query were set to select compounds having moieties matching the hydrophobic nature of the CYP2A6 active site. The plane feature in the query defined its optimal position. The smaller grey sphere indicates the position of a required acceptor/donor atom.
Database screening and analysis of selected compounds Screening the Maybridge database returned 600 molecules. After predicting their IC 50 values using the 3D-QSAR models and visual inspection, several compounds were selected and their biological activity was tested ( Table 2 ). All the selected compounds had predicted IC 50 values of less than 100 mM. In enzyme activity assay, 10 compounds showed IC 50 values lower than 10 mM. The most potent inhibitor was N1-(4-fluorophenyl)cyclopropane-1-carboxamide (IC 50 ¼ 90 nM). Interestingly, this compound was over 1100 times more potent than several closely related structures, such as N1-(4-fluorophenyl)acetamide (IC 50 4100 mM). The presence of 
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Rational design of CYP2A6 inhibitors In addition, 13 other chemicals including pyridine, benzaldehyde and benzylamine derivatives were measured for their inhibition potency (Table 2) . Benzylamine derivatives were also quite potent inhibitors, especially those with chloro or bromo substitutions at the meta position as well as chloro substitutions at the ortho-position, since their IC 50 values were below 1 mM. Interestingly, 4-benzylpyridine derivatives were 10 times more potent inhibitors than the corresponding 4-benzoylpyridines, indicating that the presence of a carbonyl group at the sp 2 carbon reduces inhibition potency.
The CYP selectivity of four most potent inhibitors was characterised with human liver microsomes as the enzyme source. As shown in Table 3 , these compounds (N1-(4-fluorophenyl)cyclopropane-1-carboxamide, 4-bromobenzylamine, 2-chlorobenzylamine, p-dimethylaminobenzaldehyde) inhibited preferentially CYP2A6. These compounds, except p-dimethylaminobenzaldehyde, inhibited also CYP2B6 activity at higher concentrations. The CYP selectivity ratios are listed in Table 4 . Relative CYP selectivity ratios are calculated as IC 50 (CYPX)/IC 50 (CYP2A6). Judging from the selectivity ratios, the most selective inhibitor was 2-chlorobenzylamine, which was 17 times more potent in inhibiting CYP2A6 than CYP2B6. This compound inhibited other CYP forms much less, as the selectivity ratios for other CYPs varied between 30.9 and 4222 (Table 4) . Substrate concentrations were close or clearly below the apparent K m values for indicated CYP activities. At these low concentrations The CYP2A6 crystal structure with coumarin, methotrexate, 24 N,N-dimethyl(5-(pyridin-3-yl)furan-2-yl)methamine, N-dimethyl(5-(pyridin-3-yl)furan-2-yl)methamine, and dimethyl(5-(pyridin-3-yl)furan-2-yl)methamine 25 and our homology model differed with respect to the amino acid forming a hydrogen bond to the substrate. We therefore generated a new CoMFA model using the coumarin-bound CYP2A6 crystal structure. 24 Before creating the model, the structure was relaxed by molecular dynamics simulation (GROMACS). The new CoMFA model was created in the same way as the initial one and all the statistical values obtained were significant (data not shown).
3D colour contour maps of the new CoMFA model with nicotine as the reference structure are illustrated in Figures 4  and 5 . The new model showed more accurately the location of the hydrogen bond. The main difference between these two models was the position of the second negative charge favourable (red) region, which in the new model was located above the five-member ring of nicotine. The interaction with the substrate (coumarin) and CYP2A6 protein is shown in Figure 5 . The map includes an area where negative charge was linked with increasing inhibition potency near Asn297. The CYP2A6 active site is surrounded by mostly lipophilic Figure 5 CoMFA fields of the model combined with crystal structure with coumarin as the template structure. CoMFA electrostatic fields: blue, negative-charge disfavoured area: red, negative-charge favoured area. CoMFA steric field: green, bulk favoured area; yellow, bulk disfavoured area. Figure 4 CoMFA fields of the model combined with crystal structure with nicotine as the template structure. CoMFA electrostatic fields: blue, negative-charge disfavoured area; red, negative-charge favoured area. CoMFA steric field: green, bulk favoured area; yellow, bulk disfavoured area. 
Discussion
This study shows that 3D-QSAR analysis can be successfully applied in the design of potent and selective inhibitors of the nicotine metabolising CYP2A6 enzyme. We have shown previously that 3D-QSAR methods are useful approaches if one wishes to evaluate the structural features that are important for inhibition potency against CYP enzymes and other targets. 23, 27, 28, 31, 32 In this study, we showed that novel CYP2A6 inhibitor structures can be designed using CoMFA based on homology modelling. As CYP2A6 crystal structures became available during this work, we were able to ascertain the accuracy of the CoMFA model using the crystal structure data.
The 3D-QSAR models created in this study add to the data we have published previously. [21] [22] [23] Use of the crystal structure 24 in the alignment of ligands improved the current QSAR model since the protein-ligand interactions are taken into account more precisely. Especially in the crystal structure-based CoMFA model, electrostatic and acceptor fields revealed where the hydrogen bond acceptors or donors should be located in the inhibitor molecule. The influence of hydrophobicity on inhibition potency was emphasised in both the CoMFA and CoMSIA steric and hydrophobic fields. These fields indicated that the presence of hydrophobic bulky groups near the metabolising site of nicotine led to an increase in inhibition potency. These fields were useful when the search query was planned. The predicted IC 50 values for most of the new inhibitors agreed quite well with the actual values although their structures did not resemble the ones in the training set.
In the crystal structure, Asn297 acts as a hydrogen bond donor to the carbonyl oxygen of coumarin. Asn279 is surrounded by mostly lipophilic amino acids which limit the size of potent inhibitors. 24 The present crystal structurebased 3D-QSAR model also showed that a hydrogen bond with Asn297 and van der Waals interactions between the hydrophobic amino acids and inhibitor is an important determinant of inhibition potency. The CYP2A6 crystal structure shows that in suicide inhibitors electron-rich regions coordinate to haem iron. 25 In the current CoMFA models, the negative charge favourable (red) regions above the haem iron indicate that inhibition potency correlates with electron density.
The novel inhibitor molecules identified in this study differ in structure from the recently reported nicotine derivatives. 25 Some of the novel compounds were very potent, especially N1-(4-fluorophenyl)cyclopropane-1-carboxamide. The cyclopropyl group in this compound is very important for the interaction since it increases hydrophobicity. The CYP2A6 crystal structure revealed that the enzyme has a very compact active site containing several hydrophobic amino acids. 24, 25 The physicochemical properties of the most potent inhibitor (N1-(4-fluorophenyl)cyclopropane-1-carboxamide) was optimal and effectively filled the CYP2A6 active site. Docking of this molecule in the crystal structure showed that it interacts effectively with the hydrophobic amino acids in the active site (data not shown). The inhibitor also includes a donor NH group which can form hydrogen bonding with Asn297. This kind of donor feature has not been considered to be important for CYP2A6 inhibition previously. The benzylamine derivatives (4-chlorobenzylamine, 4-bromobenzylamine and 2-chlorobenzylamine) were also potent inhibitors. All these compounds contain an amine group and an aromatic ring both of which are believed to be important for inhibition potency. The amine group in the benzylamine derivatives is the donor in hydrogen bonding with Asn 297, thereby increasing inhibition potency. Optimal halogen substitution and hydrophobicity features of inhibitors also increase inhibition potency. These compounds are also selective inhibitors of CYP2A6 with some effect on CYP2B6, another nicotine-metabolising enzyme. 6 There is considerable interest in the development of clinically useful inhibitors of the CYP2A6 enzyme. 12, 16, 17 None of the currently known CYP2A6 inhibitors are suitable for routine clinical use and thus there is a need to develop novel inhibitors with suitable potency, selectivity and toxicity profiles. In conclusion, protein homology modelling, 3D-QSAR and chemical database screening proved to be valuable approaches in identifying the structural features that are important for CYP2A6 inhibition and searching for novel inhibitor candidates. One of the compounds found in this study, N1-(4-fluorophenyl)cyclopropane-1-carboxamide, proved to be a potent and reasonably selective inhibitor and may represent a lead compound in the design of inhibitors to be used as adjuvant drugs in smoking cessation therapy.
Materials and methods

Homology model
Initially, there was sufficient information available about the mouse CYP2A5 protein to construct a CYP2A5 comparative model based on the CYP2C5 crystal structure. 33 Details of the CYP2A5 homology model were published recently. 34 This model was used as a template for the current CYP2A6 model because of the relatively high sequence similarity (82%) between the CYP2A6 and CYP2A5 proteins. The final CYP2A6 model was validated by checking its stereochemical accuracy and docking procedure as well as performing a molecular dynamics simulation.
Docking
The crucial step in constructing a 3D-QSAR model is the alignment of the training set molecules. The training set of chemicals used in these models is an extension of our previously published dataset. 23, 35 The training set of chemicals consisted of 80 compounds covering IC 50 values Rational design of CYP2A6 inhibitors M Rahnasto et al between 0.55 mM (2-bromonaphthalene) and 35.4 mM (cotinine). Since the coordinates of the active site of the CYP2A6 protein were known from the homology model, we applied the virtual docking tool GOLD 36, 37 to fit the ligand molecules into the active site. Virtual docking tools generate different possible conformations and orientations of the ligands at the active site and evaluate the free energy of binding by a scoring function. In the present study, the empirical scoring function ChemScore was applied 38 since it has been shown to reproduce correctly the complex geometry in the crystal structures of other CYP proteins. 39 The best docked conformations according to the ChemScore scoring function were used to construct the 3D-QSAR models.
CoMFA and CoMSIA analysis Both CoMFA 36, 40 and CoMSIA [41] [42] [43] were created for the CYP2A6 enzyme. These methods correlate the variation in the property fields in a set of molecules, such as steric, electrostatic or hydrogen bond acceptor and donor fields, with the variation in their biological activity. The outcome of these methods is a statistical model that can be used to predict the inhibition potency of unknown compounds for CYP2A6. Furthermore, the contour fields that contribute significantly to the models yield insights into the CYP2A6-inhibitor interactions. The CoMFA and CoMSIA methods differ in the way that the property fields are calculated.
In CoMFA, electrostatic and steric interaction fields were calculated, and in CoMSIA, steric, electrostatic, hydrophobic, hydrogen bond acceptor and hydrogen bond donor similarity indices were calculated using the SYBYL default settings. The resulting partial least squares (PLS) models were validated using the LOO method, 2 random-group crossvalidation method LHO or 5 random-group validation method LSO. Both LHO and LSO cross-validation procedures were repeated 20 times, and the average statistical values were calculated. Also, a progressive scrambling method was applied to validate the models, because this provides valuable information when one analyses a large dataset containing redundant information. This novel validation technique was developed to address the overly optimistic cross-validation or response randomisation results for redundant data sets. In this approach, small random perturbations are introduced into a data set. This causes the nominal predictivity of unstable models to fall off rapidly, whereas robust models are relatively stable. 44 Progressive scrambling of the biological data produces three statistics. Q 2 and cSDEP values characterise the predictivity of the model and the calculated cross-validated standard error, respectively. The current CoMFA models were shown to be stable, and the adjusted statistical values Q2 and cSDEP were comparable with the corresponding q2 and S PRESS of cross-validation. The third statistic from progressive scrambling is the instantaneous slope of the predictivity with respect to the degree of perturbation (dq 2 /dr 2 yy' ). It depicts the model sensitivity to perturbation at a critical threshold level of perturbation (here 0.85). 44 This value is reported to be a reliable indicator of model complexity, and thus, it helps to avoid over-fitting due to too many PLS components. Specifically, a number of PLS components yielding a (dq 2 /dr 2 yy' ) slope near unity should be optimal. In the case of the final CoMFA models, both cross-validation and progressive scrambling data suggested that four components were optimal.
Database screening A search query was created for chemical database mining based on the properties of both the 3D-QSAR models and the CYP2A6 active site. Naphthalene was used as template to define the query features containing a spatial plane and hydrophobic sites (tolerance 3.0 Å ). The search query contained also one donor atom (either in the protein or inhibitor) near Thr106 (tolerance 0.5 Å ). The Lipinski rule of five 45 was applied with the following cut-offs for the compounds: maximum weight 400 g mol À1 , maximum of four hydrogen bond donors and maximum of five hydrogen bond acceptors. Flexible 3D search was performed using the database searching program Unity 4.3.1 implemented in Sybyl. The Maybridge database (www.maybridge.com), containing approximately 60 000 compounds, was screened with a return of 600 hit compounds. The hit compounds were docked into the active site of CYP2A6 using the GOLD program as described before. 36, 37 The IC 50 values for these molecules were predicted with the CoMFA model. Our own database, consisting of potent and weak inhibitors, was used as positive control to test this virtual screen before the actual screening process.
The hit compounds having predicted IC 50 values in the range of 0.8-100 mM were chosen for further visual analysis. The location of the docked conformations at the active site, as well as their ability to match the requirements of the search queries and CoMFA and CoMSIA fields, was visually evaluated. Nine compounds were selected for in vitro inhibition testing based on the predicted protein-ligand conformation and new structural features. In addition, 13 other compounds were obtained and their IC 50 values were determined (Table 2) . Table 2) .
Biochemical assays
The coumarin 7-hydroxylation activity assay is based on the detection of fluorescence emitted by 7-hydroxycoumarin as described. 46 We have adapted this method to a 96-well plate format to facilitate higher throughput inhibition analysis. In each well, the 100 ml incubation volume contained 50 mM Tris-HCl buffer (pH 7.4), 5.0 mM MgCl 2 , 10 mM coumarin, 20 mg microsomal proteins and 0.3 mM nicotinamide adenine dinucleotide phosphate-oxidase (NADPH). The reaction was initiated by addition of NADPH, incubated at 37 1C for 10 min and terminated by adding 60 ml 10% trichloroacetic acid. Immediately before the measurement, 140 ml 1.6 M glycine-NaOH buffer (pH 10.4) was added. The formed fluorescence was measured with a Victor 2 plate counter (Perkin Elmer Life Sciences Wallac, Turku, Finland) at 355 nm excitation and 460 nm emission. The linearity of the reaction with respect to incubation time and microsomal protein concentration was determined. Several control incubations were carried out to determine the effect of quenching by the inhibitors and other interfering factors. Each inhibitor was pre-screened using inhibitor concentrations ranging from 0.1 to 1000 mM. The actual IC 50 values were determined using narrower inhibitor concentration ranges with five to seven concentrations. All IC 50 values were determined in duplicate both from human liver microsomal preparations and recombinant CYP2A6 enzyme. Baculovirus-insect cell expressed human CYP2A6 was purchased from BD Biosciences Discovery Labware (Bedford, MA, USA) and used according to the manufacturer's instructions.
The N-in-one multisubstrate CYP selectivity assay has been previously described in detail. 29, 30 Briefly, each incubation mixture contained 0.5 mg of microsomal protein per ml, 0.1 M phosphate buffer (pH 7.4), 1 mM NADPH and all the 10 probe substrates. Substrates, their concentrations and target enzymes for the incubations were melatonin (4 mM, CYP1A2), coumarin (2 mM, CYP2A6), bupropion (1 mM, CYP2B6), amodiaquine (2 mM, CYP2C8), tolbutamide (4 mM, CYP2C9), omeprazole (2 mM, CYP2C19 and CYP3A4), dextromethorphan (0.2 mM, CYP2D6), chlorzoxazone (6 mM, CYP2E1), midazolam (0.4 mM, CYP3A4) and testosterone (1 mM, CYP3A4). The reaction mixture, in a final volume of 200 ml, was pre-incubated for 2 min at þ 37 1C in a shaking incubator block (Eppendorf Thermomixer 5436, Hamburg, Germany) before the reaction was initiated by addition of NADPH. Each reaction was terminated after 20 min by adding 100 ml of ice-cold acetonitrile. Analysis was carried out using a LC/MS/MS method optimised for Micromass Quattro Micro triple quadrupole mass spectrometer (Micromass Corp., Altrincham, UK). 29 Human liver samples used in this study were obtained from the University Hospital of Oulu as a surplus from kidney transplantation donors. The patients have been described previously. 47 The collection of surplus tissue was approved by the Ethics Committee of the Medical Faculty of the University of Oulu, Finland. The livers were transferred to ice immediately after the surgical excision, cut into pieces, snap-frozen in liquid nitrogen and stored at À80 1C until the microsomes were prepared by standard differential ultracentrifugation. A weightbalanced microsomal pool of seven liver microsomal preparations which have been extensively characterised to be used for the primary screening (sufficient model activities, no known polymorphisms, expected effects of model inhibitors, quantification of CYPs by western blotting) was employed. The final microsomal pellet was suspended in 100 mM phosphate buffer pH 7.4. The use of human liver microsomes as an enzyme source is justified by the fact that the coumarin 7-hydroxylation reaction is mediated exclusively by the CYP2A6 enzyme in human liver. Therefore, in vitro inhibition of coumarin 7-hydroxylation in human liver microsomes reflects solely inhibition of CYP2A6 enzymes with no participation by other CYP forms. 
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